IAPO Intematlonal AllIan of Patients. Organizations Chwty reglstratim nnber{EnSIand and Wales>.1155577 Intemational Alliance of Patients, Organizations (Incorporated as a Company Limited by Guarantee and not having a Share Capital) Annual Report and Financial Statements forthe Year Ended in December 2025
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Contents Reference and Administrative Details of The Charity, Its Trustees and Advisers Trustees, Report for the Year Ended 31 December 2025 Independent Auditor's Report to the Members of International Alliance of Patients, Organizations forthe Year Ended 31st December 2025 35 Statement of Financial Activities Ilncorporatfng an Income and Expendlture Attountl for the Year Ended 31 December 2025 39 Balance Sheet as at 31 December 2025 40 Notes to the Financial Statement5 for the Year Ended 31 December 2025 41
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Reference and Administrative Detsils of the Charityj Its Trustees and Adviser5 Company number 08495711 (England and Wales) Charlty number 1155577 (England and Wales) Registered office International Alliance of Patients, Organizations Canopi, 82 Tanner Street, London, SEI 3GN, UK Governlng Board members IBoard of Trustees) Profe550r Lara Claire Bloom Orajitt Bumrung5kulswat Flavia Kyomukama Paul Albert Sumat Mendoza Fernanda Souza de Carvalho Agron Bytyqi Dr. Ratna Devi Vasiliki-Rafaela Vakouftsi Waèl Kamel Ali Ali Mazrouh Iloined 15 Nov 20251 Chief Exècutive Daniela Espindula Mothci Bankers Natwest Bank PIC PO Box 12258 I Princes Street LONDON EC2R 8BP Independent auditor Knox Cropper LLP 65 LÈ8dÈnhall StrÈet London EC3A 2AD Website
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 The directors, who are also the trustee5 of the charity, are pleased to present their report together with the financial statements of the charity for the year ended 31 December 2025 which are also prepared to meet the requirements for a directors, report and accounts for Companies Act purposes. IAPO Trading Limited Icompany number 088631901 wa5 dormant and wa5 di55olved in July 2024. The trustees have complied with the duty to have due regard to guidance issued by the Charitv Commission and have adopted the Statement of Recommended Practice for charities ISORPI IFRS 102 second edition effective I january 20191. Aims and objectives of the organisation The International Alliancè of Patiènts, Organizations IIAPOI is a global alliance of patiènt organisations working Bcross all disease areas, region5 and populations tg advance people-centred healthcare. We mobilise and 5UPPOrt patient organisations worldwide, strengthening their capacity to represent patient5, families and carers and to play an active role in shaping health policy, research and healthcare systems. By connecting patient organisations, amplifying their collective voice and providing opportunities for collaboration, learning and advocacy, IAPO helps ensure that health systems are shaped by the needs. preferences and lived experiences of the people and communities they serve. Through our global network and engagement with international health insritutions, we work to foster patient-centred healthcare and improve health outcomes. IAPO wès first established in 1999 in the Netherlands as a Dutth Stichting and subsequently deregistered, registering in England and Wales a5 3 company limited by guarantee on 19 April 2013 and 3 charity on 30 January 2014. IAPO has a membership of nearly 300 organisations across 74 countries covering 52 disease groups. IAPO is a Non-state Actor in official relations with the World Health Organization (WHO) and has a consultative status with the United Nations Economic and Social Council. IAPO has a memorandum of understanding with a variety of organisations including the International Council of Nurses IICNI, International Hospital Federation IIHFI, International Pharmaceutical Federation IFIPI, World Medical sociation IWMAI.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 IAPO'S vlslon and mlsslon IAPO'S vlslon and mission was updated in 2024 following the organisation's 2 h Anniv VTs¥on A workl there heath systemsare sh4)ed by UnPaUFy noeds arKI Mission Md)lise 8nd pthnt erganisat1tinsartm ttr vd,emrX?werfrfj them to play ah¥li¥è rde (¢110n maing proCssesslwn91 a1 In 2025, IAPO continued its mission to help build people-centred healthcare worldwide by: Empowering patients. organisations. maximizing their impact through capacity building Advocating internationally with a strong patients. voice on relevant èspects of healthcare policy, with the aim of influencing international, regional and national health agendas and policies Building cross-sèctor alliantes and working collaborativèly with like-mindèd medical and health professionals, policy makers, academics, researchers and industry representatives IAPO'S artivities include: Advocacy at global level on relevant aspects of healthcare policy to influence international health agendas and policies Providing membership services, including capacity building and shared learning, to its members, who 3re patient-led organisations 3cr055 the world Empowering its members to undertake their own advocacy at regional and national meetings Providing opportunities for stakeholders from across the health sector to meet and work together to advance patient involvement in health services and decision-making Research on emerging areas of interest to patients, organisations and to underpin the evidence base for showing the importance of patient Involvement to public health.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Structure The organisation is a charitable company limited by guarantee, incorporated on 19 April 2013 and registered as a charity on 31 january 2014. The company was established articles of association which deline the objects 2nd powers of the company and its governante arrangements. In the event of the ompany being wound up member5 are required to contribute an amount not exceeding £1. All assets and liabilities from the International Alliance of Patients Organizations and its predecessor not-for-profit structure registered in the Netherlands, were transferred to the new UK incorporated charitv on l February 2014. IAPO Nethèrlands was Ivoluntarilyl dissolved from thÈ Netherlands TradÈ RÈgistÈr with effert from 31 May 2015, executed on 21 October 2015. Appointment and induction of Governing Board Every member of the IAPO Governing Board is elected by IAPO'S members. through a process defined in the arhcles of Association b -laws and election code of conduct. Every year, in advance of the annual general meeting IAGMI, the number of vacancies on the Board 15 notified to all members, who may then nominate someone from their organisations la Board member or senior staff member) to IAPO'S GDverning Board. The full list of nominees is sent to all members in advance of the AGM- members mav vote by post or proxy or in person at the AGM. Governing Board members serve for a maximum of two terms subject to the retirement by rotation clause,. once their term of service is complete. they or anyone from their organisation cannot be re-elected to the Board for at least a year. All new members of the Board receive induction including core information about the work and history of the organisation, and conversations with the Chief Executive Officer and the Chair. All Governing Board members sign a code of conduct when they are appointed to the Board. All stsff and Governing Board members are required to declare any relevant conflict of interests or conflict of loyalties at Èvery Board mÈeting, or betwÈÈn meetings if applicable. Thè Governing Board has no beneficial intèrest in the charitable company or it5 trading 5ub5idiary. No Governing Board member receives any remuneration, but some receive reimbursement for essential travel or similar expen5e5.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Governance The International Alliance of Patr'ents. Organizations has a Board of Trustees and Directors overseeing its governance and direction, supported by a secretariat headed by the Chief Executive Officer. Board of TrusteeslDirertor5 Name Professor Lara Bloom I Position Chair Country United Kingdom Philippines Thailand Dates Mr. Paul Albert Mendoza Mrs. Orajitt Bumrungskulswat Secretary Board Member Ms. Flavia Kyomukama Treasurer Ms. Fernanda SoLJza de Carvalho Board Member Board Member Board MÈmbèr B03rd Member Board Member Uganda Brazil Mr. Agron Bytyqi K050VO Dr. Ratna Devi India Ms. Va5iliki-Rafael3 VakoLJftsi Greece Dr. Wael Kamel Ali Ali Mazrouh Egypt Since 15 Nov 2025 *auaiJpd IPqOIy '
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Public benefit The Governing Board tonlirm5 that they have considered the guidance contained in the Charity Commission's general guidance on public guidance when reviewing the charity's aims and objectives. They consider that the activities carried out, summarised in the Achievements and Performance section of this report, provide benefit to the public. IAPO'S objectives are the promotion of the relief of sickness and the preservation and protection of health for the public benefit. IAPO pursues this through fostering parient-centred healthcare worldwide and, in parbcular, by developing the capacity of patient5, or8anisations. In sethng our objectives 2nd planning our activities trustees have given consideration to the Charitv Commission's general guidance on public benefit IPBI, PB2 and P831 and have taken these into account in making all decision5. We have not departed from the guidance in 2025. IAPO'S services are open to all people and our membership reflects a diverse group of patients, organisations representing patients with communicable and non-communicable diseases, including patients with diseases that are stigmatised in many societies. IAPO had 278 members comprising umbrella groups and single organisation5 in 2025 who directly represented views of over I million patients in 72 countries across 54 disease areas. The service5 the charity provides are designed to build the capacity of patients, organisations, allowing them to better assist the needs of patients and CarS land their own member patient organisations in some cases) from across the world. Access to IAPO'S website is freely available to the public. Currently it is in English, with some sections in Spanish. The website Contains a wide range of information on IAPO'S activities and on patient-centred healthcare. which is of benelit to the public. particularly those who wish to set up local patients, org3nisations. By improving access to information, training and other capacity building programmes for patients and their representative organisations, IAPO improves access to healthcare itself. By raising awareness and through capacity building and education, we increase access to acceptable services that respect patients, preferences, values, rights and needs. IAPO has a wealth of evidence, gained from patient5, organisation5 worldwide, which demonstrates that patient involvement in patient5, care leads to better health outcomes and lower costs for the whole of society. The charity works with patients. organisations that are not for profit and non-governmental organisations who demonstrate commitment to improving p3tient-centred healthc3re which 15 reflected in the charity's membership criteria.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Chair's Report for the Financial Year 1st January to 31st December 2025 If 2024 was 3 year of transition 2nd renewal for IAPO- laying h.rm foundations and sethng a clear strategic direction then 2025 was the year in which we put that strategy into action. Building on the FACE framework launched in 2024. IAPO moved with purpose and confidence. translating our renewed vision into tangible impact for the global patient organisation community. Across all four pillars Facilitation. Advocacy, Collaboration and Empowerment- 2025 was defined by delivery, deepened partnerships, and a growing recognition of IAPO'5 voice on the world stage. For the first time, our Global Patients Congress was held in Asia, bringing together MO than 200 parhcipant5 in Manila, Philippines, and online. The Congress highlighted the power of patients, voices and lived experience in shaping health systems worldwide. A key outcome of the Congress was the launch of the Global Patient Charter on Social Participation, a practical framework to help patient organisations engage governments and advance meanineful partr'cipation in health decision-making. Our influence within global health institutions also continued to grow. IAPO'S status as a Non-state Actor in official relations with the World Health Organization IWHOI was renewed. 2nd a new three-year Collaboration Plan w35 approved. Through our engagement at the World Health A55embly and other high-level global forums, we ensLJred that patient persP@ctive5 informed discussions on patient safety, quality of care, Social participation and universal health coverage. Partnership rèmained central to our work. Together with fivè leading global hèalth organis8tions, we adopted the healthcare Sector's kn.rst joint ethic31 principle on the responsible use of health data, technology and artificial intelligence through the International Consensus Framework for Ethical Collaboration. We also continued to support the ratification of the African Medicines Agency Treaty, helping advance efforts to strengthen access to safe and effective medicines across Africa. At the heart of these achievements are our members. Through increased opportunities to engage in our programmes and initiatives, we continued to connect, support and amplify patient organisations around the world, strengthening our collective impact and advancing patient-centred healthre. In 2025. we made 3 number of strategic investments to strengthen IAPO'S organisation31 capacity, intluding thè rècruitment of 3 Communications officer 8nd èngagement with specialist consultancies and professional services to further enhance our sustainability, operations and governance. These investments were an intentionzl and forward-looking decision, enabling us to deliver the ambitious programme of work outlined in thi5 report while building the foundation5 for future growth. Supported bv strong cash reserves, we were well-positioned to invest in the organi5ation's long-term resilience and impact.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 The board remains confident that these decisions will help position IAPO for its next phase of development, ensuring we continue to strengthen our voice, expand our reach. and deliver value for our members and the wider patient organisation community. Building on our progress in 2025. we move forward with momentum. conlidence and a clear sense of purpose, leaving us well placed to continue advancing people-centred healthcare and to ensure that the voices of patients and people with lived experiente remain at the heart of Èlobal health. None of this would have been possible without the dedication of our member organisations. the commitment of our staff and leadership team. and the generosity of our partners and funders. On behalf of the governing board, l extend my sincere gratitude to all of them. Professor Lara Bloom Chalr of IAPO Governlng Board io
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Achievements and Performance The International Alliance of Patients. Organizations- IAPO is a pioneer alliance representing the global voice of alrn05t 300 patient org3nisahons acr055 all disease areas and from all regions of the world. We were established in 1999 to co113borate on common agendas for the patient organisation community and address challenges that transcend national borders. In 2025, IAPO continued its journey of collaboration, advocacy and innovation to empower the patient organisation community and advance people-centred healthcare globallv. Since 2007, IAPO has held the status of Non-state Actor in official relations with the World Health Organliatlon. This status is granted to entities that are international in membership and scope and tontribute signifitsntly to the advancement of public health. IAPO also has a speclal consultative status with thè United Nations Etanomit and Sotial Countil since 2014, allowing us to actively engage with the Council, the United Nations Secretariat, and across programmes, fund5 and agencies in several ways. The FACE Framework This report presents our 2025 highlights organised around the major initiatives and workstreams that defined OLJr year. Each is mapped to IAPO'S im act strate the FACE framework (Facilitation, Advotaty, Collaboration and Empowerment), launched during our 25, Anniv n in 2024. Facilitation Advocacy Collaborntlon , Representhg the t&reEt5 tient orfjar¥qotions pIdInq impa¢tfyl 8Dd ryanisatl¢)ns Flcally lo 1 5U8t•lnatle partn¢F$hip5 raise 48ne$S end inflvpn¢e p¢V stakehelrerallarrt¢s to deers-m81rtg thJl l advarKe •uend8s forthe rolt Ihv and 91ob¥ patienl prelerence5 Ot the 0194ni$ation corrmuntty. vmmuniti¥s Ihey pPrtingfhe dovuknpm4nl g(polie Orn1$tIonS. C8p3bilti and l¢sl¥rfng 4 c¢mmufjity tor utowt dnd GollDratiDn. through re$Irces, ¢¥gnlb, Itaining 4tKI I..an9nfj knowledg btssl pr¢L11¢95, and ¥ative 8ppr08che$ 10 VonG¢ glot>al health li
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Bècause our work is deeply interconnected, most initiativès advance more than one pillar of the FACE framework at once. The table below mBp5 the year's work onto the four pillar5 Ht a 8lance. What it meant in 2025 Learn about it in section Facllitatlon Representing members,. exchanging knowledge and evidence 2. Engagement with the WHO and the multilateral system 5. Research and evidence 6. Strengthening our membership and community Advocacy Influencing policy and decision-making l. Universal Health CoveraEe and Social Participation 2. Engagement with the WHO and the multilateral system 3. African Medicines Agency Treaty Alliance IAMATAI Collaboratton Building partnerships and alliances 2. Engagement with the WHO and the multilateral system 3. African Medicines Agency Treaty Alliance IAMATAI 4. Personalised Cancer Care Alliance IPCCAI 7. Wider partnerships and sector collaboration Empowerment Building mèmber capability and community l. UnivÈrs81 HÈ8lth CovÈrage and Social Partitipation 4. Personalised Cancer Care Alliance IPCCAI 6. Strengthening our membership and community Thgc•naboYakn T* ollhè 91obulpaiiortoryunltaiian rvmTroythyln4Jdvunelng soclalportldpgtlonl un1v•rsaih1th<oYgl
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 l. Universal Health Coverage and Social Participation Advancing.. Advocucy . Empowerment. Fucilitation Universal health coverage IUHCI and social participarion sit at the centre of IAPO'S mission. In 2025 thev were the through-line connecting several of our flagship initiatives- from the launch ol the Global Patient Charter on Social Participation to the continued growth of the UHC Compass. Global Pauent Charter on So¢lal Partl¢lpaUon A landmark initiative launched at IAPO'S Ilth Global Patients Congress in Manila in November 2025, the Global Patient Charter on Social Partici ation 15 a practical advocacy tool designed to help patient organisations in engaging governments and promoting locally rooted and context-sensitive social participation. It was developed as part of IAPO'S efforts to promote social parkncipation in line with the World Health Assembly resolution on social participation for universal health Coverage. health and well-being adopted in 2024, and offers concrete benchmarks for what meaningful social participation shoLJld look like. It was co-created over several months through the collective input of more than 35 IAPO members and an advi50ry groLJP of over 20 health expert5, including WHO representatives, three 515ter organi53tions IRare Diseases International, the European Patient5, Forum, and Patient Movement Cataly5tl and partners such as NCD Alliance, UHC2030, CSEM, and the Lancet Commission on People-centred Healthcare. The task force met throughout 2025 to provide valuable feedback on drafts of the Charter. and rounds of consultations with key targeted groups also took place. In October 2025, the WHO Civil Society Commission offered IAPO the opportunity to present the draft Charter to its members across the wider civil society community and Eather their feedback. Following the launch in November, the Charter was disseminated across different regions. with very encouraging reports about its uptake. World Health Organization UHC2030 Task Force Established in 2022, the UHC2030 Task Force leverages its expertise and networks to sustain momentum for the implementation of universal health coverage and advises the UHC2030 Secretariat on accountability for results. In 2025 IAPO was invited to join the steering committee of the task force and serve as a representative of the patient organis8tion community. Thè task force convenès rèpresentativès from various conthtuencies to ensure accountability for, and drive the implementation of, the UHC Political Declaration. 13
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 The work focuses on the development of thè new COLJntry profile dashboards for the 'From Commitment to Action.. A Global UHC Action Tracker Report,, as well a5 on elevating the key findin85 and recommendations to policymakers once the data analysis is concluded. UHC Compass Theu Q£omuass was developed by the Global Patient Think Tank IGPTTI which was convened by Roche. IAPO was one of the GPft members and chosen to tarry on the work of the UHC Compass. In 2025 we continued developing the tool bzsed on user feedback and exp3nded its reach and impact through engagement with key stakeholders, networks and events. We started the digitali5ation of the Compass into an online platform with an integrated feedback survev. IAPO delivered four se55ion5 on the UHC Compass for patient organisations attending the regional International Experience Exchange with Patient Organisations IIEEPOI workshops in Latin America, Africa, Eastern Mediterranean and the Asia-Pacilic workshop.
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Patlent Solldarlty Day Patient Solidari Da PSD takes place every December. when patients and people with lived experience around the world unite to spotlight a key issue affechng our global patient organisation community. Patient Solid8rity Day inspires attion through soci31 mÉdia campaigns, lotal Èvents, and global convèrsations- all aimed at puthn8 patients at the heart of healthc3re. We celebrated PSD on 3 December 2025 under the theme 'The Global Patient Charter on Social Parhcipation,, championing the importance of meaningfLJI engagement of patients and people with lived experience in health governance, following the launch of IAPO'S Global Patient Charter on Social Participation. To mark the day, we encouraged all to endorse the Charter, and created a variety of messaÉes and social media assets for members to share with their networks, amplifying voices and impact. Representation on UHC and social participation + IAPO co-hosted the 2 with Em for UHC2030 and other civil society organisations, in a session titled 'A youth-parliamentarian dialogue on partnering for progress towards affordable health for all,. + IAPO spoke at the Patient En ement O the plenary session and in one of the co-creation sessions. + IAPO spoke at the mFr (Frontiers of Health) in Brazil, at the opening ceremony 'Collaboration in Health.. Building Health Public Policies with a People-centred Focus, and the session 'Patients' Rights and UHC,. enF PE in Italy, about social participation at 2. Engagement with the World Health Organization and the multilateral system Advancing.. Advocacy. Collaboration . Facilitation As a Non-state Actor in official latiOnS with the World Health Organization IWHOI, IAPO works closelv with the organization acr055 adv0C¥, collaboration and technical engagement. In 2025, the IAp¢>WHO Collaboration Plan1202>20271 wa5 reviewed by the WHO Executive Board and approved at its 156th session in February, and our Non-state Actor status was successfully renewed until the next triennial review. Patient Safety and Quality of Care part of our collaboration plan with the WHO IAPO spoke at the Vll Global Ministerial Summit on EatiollL&th134 April. Philippinesl. in the opening session on the role of patients and patient organisations in improving patient safety and supporting the implementation of the Global Patient Safety Action Plan 2021-2030. 15
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 IAPO also produced the narrative review 'Putient Safttyfrom the Patient Perspective.. Unmet Needs and Opportunitiesfor Engagement., by analysing existing literature and available evidence, and emphasising its alignment with the Global Patient Safety Action Plan 2021-2030. A WHO-led initiative observed yearly on 17 September, World Patient Safet Da calls for global 501idarity and concerted action by all countries and international partners to improve patient safety. The day brings together patients, families, caregivers, communities, health workers, health care leaders and policy-makers to show their commitment to patient safety and quality of care. WPSD The activities undertaken to mark WPSD 2025 are part of the IAPO-WHO Collaboration Plan12025-20271. Some of the highlights include.. + IAPO jointly hosted a webinar with the Patients for Patient Safety Observatory on Tuesday. 16 September. titled "En in Families and Communities Protectin Eve Newborn Eve Child" The interactive session brought together leading experts from the World Health Organization, UNICEF Montenegro, Joint Commi55ion International and ICAN Ilnternational Children's Advi50ry Network) for a crucial conversation about protecting our most vulnerable patients. The session was recorded and osted on IAPO'S YouTube channel. + IAPO also took part in the WHO'S global webinar, S(7ft carefor every newborn anLI every chilLI', which took place virtually on 8 September 2025. + IAPO tailored a uide to su ani5ation5 in marking WPSD, including kev information about the campaign and social media captions for online use. ort atient or + IAPO'S full re ort of WPSD activities can be found here. Multilateral Statements A5 a Non-state Actor, IAPO is entitled to lead and join individual and constituency statements during Executive Board meetings and World Health Assemblies. At the WHO 156th Executive Board. held 3-11 February 2025. IAPO delivered an individual statement along with Fi ht the Fakes Alliance on Agenda item 12.. Substandard and Falsified Medical Products. We also joined six constituency statements, as follows.. + Two statements on universal health coverage.. one on the World Health Assembl Resolution Int rn nal and the other on Int rn in vi mm ni WHAR ni Medical Ima in Ca acit b the World Federation of Nuclear Medicine and Biol 16
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 + Two statements on health emergencies.. onè led b Global Hèalth Council and the othèr b he International Fe fph rm eutical Manufacturer5 and Associati IIFPMAI. + A statement on I h led by the World Heart Federation. + A statement on the involvement of Non-state Artors NSA5 in WHO'5 overnin by the Global Health Council. bodies led The took place on 19-27 May 2025. During the event, IAPO worked to amplify the voice of patients and people with lived experience across multiple global health discussions by delivering and joining several statements on key agenda items, such as.. + One individual statement delivered by IAPO on sub behalf of the African Medicines Agency Treaty Alliance IAMATAI, of which IAPO is founding member and holds the secretariat, and as part of The Fight the Fakes Alliance. son 17
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 + Two statements on univers31 health coverage, one led by NCD Alliance and one led by Save the Children. + One on the Follow-up to the Political Declaration of the Third High-Level Meeting on NCDS. led by the International Society of Nephrology IISNI. + One on climate change and health, led by the World Heart Federation IWHFI. During 2025, IAPO actively supported two draft resolution5 that were recommended for adoption at the 78th World Health Assembly in May.. one on rare diseases through our engagement in the Coalition in Support of the Resolution on Rare Diseases led by Rare Diseases International, and one on skin diseases. We also 5UPPOrted another draft resolution on which wa5 equally recommended for adoption atthe WHA78. In response to the recent U.S. decision5 affecting global health, IAPO issued a statement highlighting the impact on patient5 and patient organisations, reaffirming our support to the WHO and calling for global solidarity. WHA78 side events DLJring WHA78, IAPO jointly hosted four side events.. + With the Civil Socie ement Mechanism for UHC2030 on 19 May. the session. titled 'The collaborative role o the lobol tient or onisotion communit in advancin En CSEM Ci471 orticti ution or univer5t71 health £overt7 e, explored how to optimise the impact of the resolution through thoughtful and trusted cooperation and partnership at all levels. + Co-hosted with CSEM, UHC2030, The George Institute for Global Health, Global Health Council, Amref, Save the Children, NCD Alliance and Global Mental Health Action Network Iunited for Global Mental Health) on 21 May, the second event provided a platforrn for civil society to reflect on progress and explore opportunities to Strengthen the Implementation of the WHA77 resolution on social participation, particularly at national and regional levels. + With the Harvard Medical School Program in Global Primary Healthcare. UNAIDS and Gilead Scièncès, also on 21 May. Titlèd 'A Seot at the Table, the event took the form of an art exhibition on the importance of people-centred care as a key strategy in radillY re-centring and strengthening health Systems and primary healthcare. + In support of AMATA- the African Medicines Agency Treaty Alliance- and the patient saftty agenda, we co-hosted an official side event inside the UN Palais des Nations with US Pharmacopeia, International Pharmaceutical Student5, Federation and IFPMA on 22 Mav. 18
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Titled Addressin the Globol Crisis o Substandord ond Falsi ed Medicol Products, IAPO was one of the voice5 advocating ft)r immediate action, ernpha515ing the importance of involvin8 patients and civil society in tackling this crisis and calling for greater global attention to ensure medicine safety and public trust in healthcare systems worldwide. 3. African Medicines Agency Treaty Alliance Advancing.. Advocucy . Collubomtion The Afrlcan Medlclnes A enc Treat Alllance AMATA is a multi-stakÈholder alliance set up to advocatè for the ratification and implementation of the African Medicines Agency IAMAI Treaty and for meaningful engagement with patients and other relevant parties in all aspect5 of the Agency framework. In 2025 activities mainly focused on the #Afri¢anMed NOW campaign that aims to shine 8 spotlight onAMA and its significant benefits, and put pressure on decision makers to act urgently and make the agency a reality. The first wave of the campaign took place in February leveraging the Africa en 19
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Union Summit to raise awareness and gather 5UPPOrters. The campaign gained strong engagement across IAPO, AMATA. and AMATA members, on social media. IAPO developed a ' n P k. outlining how to implement the campaign across social media through sharing social media posts, key messages on AMA, national call to action cards, personalised quote cards. and a launch email template. All materials were available in English. French, Portuguese, and Arabic, ensuring accessibility 2cross Africa. At the 75th Session of the WHO Regional Committee lor Africa in August 2025. AMATA published a statement commendin Member States for the ro ress re orted under the Re ional Strate on Re ulation of Medical Produrts in the African Re ion 2016-2025 (Agenda Item 16.81. At the 78th World Health Assembly in May 2025, AMATA delivered a statement on A enda Item.. 13.5: t ndard and Falsitied Medical Pr du calling on all African Member States yet to ratify the African Medicines Agency Treaty to do so urgently. A recordin of the statement can be viewed here. At the 4th Conference on Public Health in Africa ICPHIA20251 held in South Africa in October 2025, AMATA called on the African Union and all Member States to back the AMA and to recognise regulatory system strengthening as key to a safer. healthier and MO prosperous Africa. and held a side event, ricun Medicines A enc ..Ake rere uisite oroso er heolthier and ros erous A rico" Earlier, in lune, IAPO spoke on our AMATA work at the Africa Health Excon in EEYPt, in the session 'Advancing Africa'5 Health Sovereignty.. Manufacturing, Regulation, and Procurement,. 4. Personalised Cancer Care Alliance {PCCA) Advancing.. Collaboration . Empowerment TheP nce IPCCAI is an alliance of cancer patients, carers and representatr'ves of patient organizations from within the WHO Eastern Mediterranean and selected countries from WHO Africa and Europe set up to advance health literacy in cancer, advocacy skills and education on personalised cancer care. Following a successful capacity-building workshop in late 2024 in Dubai with patient organisations from the Gulf Cooperation Council IGCCI countries, in 2025 IAPO continued to support the organisations that participated in the GCC and Morocco120241 workshops with information, resources, networking and collaborations to advance personalised cancer care nationally and regionally. A Gender Working Group IGWGI was established to craft a personalised cancer care approach that harnesses women's distinctive insights while addressing their specific needs and challenges when impacted by cancer. 20
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 In 2025 we co-created three new chapters of the Eastern Mediterranean Re ion with patient organisations of the pilots in Morocco and the GCC countries, but also Wlth the Gender Working Group members (launched in April 20261. The Gulf and Morocco chaptèrs highlight thÈ prattic818pplication of the 5Ps framework, whilè thÈ GWG chapter presents an approach tailored to women's insights and needs. We also held z workshop with the cancer patient organisations of the alliance's three streams (the Morocco and GCC pilots, and the GWGI, on the sideline5 of our Ilth Global Patients Congress in Manila, where we showcased progress across the streams, and together developed a roadmap to pave the way for 2026. JJ 5. Research and evidence Advancing.. Fucilitutlon Unmet Patient Needs Research In 2025. IAPO linalised the final report and three advocacy briefings as part of the Unmet Patient Needs Research, undertaken in 2024. The survey was co-designed with IAPO members to gather valuable insights about Ljnmet health-related needs from the perspective of patients and people with lived experience. 21
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 EOLlnPlate We continued our support to the international research ect EOLinPlace at the University of Coimbra, both as part of the Patient Adviso Gmu and as the project's patient representative, participating in ular adviso and workin rou meetin ro part of our contributions to the project IAPO spoke at the EOLinPlace event 'Read rEndo Pla Place held in May in Finland. and in attended the EOLinPlace Annual General Meetin held in lune in Portugal. In September 2025, we co-hosted with the research team a consultation webinar exclusivel IAPO members to SLJPPOrt the vzlidation of the International Classifitation of in Plates Common metric to classi where eo le die and are cared for at the end of life which is one of the project's rNain research deliverable5. with Icp In December 2025, IAPO moderated a focus gmup with several international organisations and key st3kÈholders with thè samè objective. The ICP was roved in 2026 b the Unlted Nations The BMJ Internaortal paent Advlsory Panel IAPO continued to participate as a member of The BMI Int within the different working groups. el, advising In November 2025, IAPO co-authored a BMJ article titled Action is needed to implement World Hetslth Assembly stsciolporticipotion resolutiOftJ'. 6. Stren8thenin8 our membership and community Advancing.. Empowerment. Focilitotion Member meetings In 2025 we held meetings for IAPO members to strengthen our connection with them and ensure alignment on our mission and priorities, providing opportunities for networking. relationship-building. collaboration, and identifying new shared agendas. 22
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Patient Academy In 2025, three new vide05 were developed for the Patient Atadem latform on.. regulattsry affairs, sotial pathcipation, and unmet patient needs from the patient perspective Ishowcasing the results of our survey). IAPO members were involved in reviewing the scripts and vide05 to ensure they are meaningful for our community. Global paentS Congress IAPO held the Il, edition of Dur flagship event, Global Patients Con GPC from 16-17 November 2025. The event, held in Manila Iphilippinesl brought together our global membership alongside a diverse range of hÈalthtare stakÈholdèrs to explorÈ key topics toncerning patients and people with livèd experience around the world, as well a5 OPPOrtunitie5 for collaboration on shared solutions. We were delighted to welcome almost 200 attendees to the event, both virtually and in person. ress The event was co-hosted with IAPO member Psoriasis Philippines IPsorPhill. and explored the theme 'From Voices to Action.. Patient OrganisGtions ShtJping HEulth System TrGnsforrn(Ftion' across 12 inspiring sessions. Speaker5 and moderators included patient representatives and people with lived experience, as well as stakeholders from World Health Organization, NCD Alliance, Globalskin. Rare Diseases International, The Synergist, Roche. Boehrineer Ingelheim, International Council of Nurses, ICHOM. and Harvard Medical School. Li
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Se55ion5 included an Opening Plenary from IAPO and WHO representatives, and Teodoro Javier Herbosa, Secretary from the Department of Health. Philippines on the topic 'Why Participation in Het71th in Non-negott'uble,. Other sessions discussed important topics such as, 'How con lived experience inform and strengthen globol heolth commitments t7nd nutional implementotion? Turning politicol ogreements into notional heolth strL7tegies', 'Eouity in Heolth, MokinL7 universol heolth covero9e workfor ptsrients. reol need5, Prototyping mode15 Of cure U5ARg patient journey5. and sharing 'best pructicesfor co-creotion with putients in health-reluted innovation,. The event also included an open dialogue session on 'Who holrjs the power? Rebolrjncing health ecosystems., and two Hackathon sessions on From tokenism to metsningful ptsrticipotion heolth-decision making,. A highlight of GPC 2025 was the launch of the Global Patient Charter on Social Partici well-received and marked the start of the campaign to disseminate the tool worldwide. ation which was Additionally, on 15 November, the IAPO members, day took place with IAPO'S annual general meeting, followed by a Learning Lab that Eathered insights from members on the UHC Compass, the Charter, and the development of IAPO'S Regional Hubs. Expert dialogue5 In July 2025, IAPO held a couple of dialogue5 between members and expert5 from different field5, providing an informal environment for learning. Speakers included representatives from ICHOM and EUPATI covering key topics for our community, including patient engagement in research and development, value-based hezlthcare. 7. Wider partnerships and sertorcollaboration Advoncing.. Colloboration International Consensus Framework for Ethical Collaboration The International Con5en5us Framework for Ethical Collaboration ICF was est3blished in 2014 a5 B global platForm to ensure that relationship5 across the health ecosystem are grounded in ethical, transparent, and responsible decision-making. It unites six leading health bodies representing patient organisations. healthcare professionals, and the pharmaceutical industry. On 26 June 2025, IAPO and the other five leading international organisations- representing patr'ents, physicians IWMAI, pharmacists IFIPI, nurses IICNI, hospitals IIHFI, and the pharmaceutical industrv 24
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 IIFPMAI- adopted the first joint ethical principle in the healthcare sector on the responsible use of health data and technology. including artr'licial intelligence. The updated version of the ICF was launched via a jiLL0sla%2 and an online promotional In campaign. Following this. IAPO sent a specific communication to members highlighting the framework's value and encouraging them to use it. Memberships. councils and agreements IAPO joined Patient Focused Medicines Develo PFMD to represent the global patient organisation community in this mulri-stakeholder initiative. PFMD continues to expand its scope of work and address patient engagernent across different areas, well aligned with IAPO'S mi55i0n. ment IAPO joined the International Consorknum for Health Outcomes Measurements IICHOMI'S Patient Partner Alliance. IAPO became part of the Steering committee of the HTAI Interest Grou Inv in HTA The PCIG brings together patient5 and citizens with staff from HTA bodies, government, research, industry Ihealth technology developers) and consultancy to strengthen HTA with the systematic incorporation of patient and citizen perspectives. for Patient and Citizen IAPO wa5 again invited by the International Hospitsl Federation IIHFI to serve a5 a member of the which took place in November in Geneva. IAPO continued to actively participate in the discussions and consultations of the Commlsslon of which we are members, and its selected working groups. IAPO joined the Joint Commission International'5 member. il as a founding Representation at external events IAPO was 3150 represented at a number of further event5 durin8 the year.. + the Patient Involvement Symposium hosted by the European Federation of Periodontology, held in May in Austria., + the 16th International Conference on Medical Regulation organi5ed by the International Association of Medical Regulatory Authorities IIAMRAI, which took place in Ireland in September 2025. We presented the patient perspective to an international audience of regulators and health 25
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 professional bodies, speaking in the opening plenary 'Community Expecttstions- Whtst Reolly MottersP'; + the International Consorknum for Health Outcome5 Measurement Conference IICHOMI held in Ireland at the session "Driving Change Through Potient Voices," and the ICHOM Leadership Forum,. + the side event organised by the Infectious Disease Alliance, titled Health Without Borders.. Integroted Primary Heolthcorefor All,: and + the webinar'striving for Balanced IP Systems,, which launched the IGBA report 'GamiNg the system- An overview of originator companies evergreening strategies used to hinder access to generic and biosimilar products,, organised by the International Generic and Biosimilar Medicines Association IIGBAI in February. IAPG
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Communications IAPO maintained its newsletter subscription of over 14,000 subscribers, who receive our announcements, campaigns 2nd regular newsletter covering all IAPO-related news 2nd updates, including initiatives such as our congresses, mernber activitie5, advocacy news and information. We added to the newsletter a section on relevant updates about the World Health Organization IWHOI. including new policy documents and guidelines. important dates and advocacy campaigns. We also added a section on upcoming events IAPO will be attending. We used several mailing campaigns to disseminate and promote important IAPO initiative% and events throughout the year. x Iformerly Twltter} The IAPO secretariat continued to operate the following X accounts: AfricanAmata PCCAlliance. Facebook We Continued to operate the following Facebook accounts.. IAPOvoi Or anization5 Patient Solidari Da Personali5ed Cancer Care Alliance. rn tional Alli8n of Pati nt Llnkedln IAPO also continued to operate the following Linkedln account5.. Or anizations African Medicines A enc Treat Alliance AMATA Personalised Cancer Care Alliance. YouTube We continued to operate IAPO'S YouTube channel- 238 videos. IAP which 15 currently composed of Instagram In November 2025 we launched an Inst3gram account IAPO voice, connecting with as many of our members a5 P055ible. We've currently shared 31 post5, and reached an audience of over 1,200 account5 in the last 90 days IDec-Mar 20261 Blueskv In December 2025 we also launched a Bluesky account ovoice.bsk .social. 27
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Website www.ia o.or continues to be the main source of information for all IAPO'S activities, initiative5 and events, as well as an important promotion and dissemination channel. We have spent 2025 designing and implementing a new website. due to be launched in 2026. UHC Compass landing paBe www. Sponsorship 2025 IAPO Sponsorship 2025 IAP GSK Roche VIATRIS" Gold Sponsor Bronze Spon50r Sponsor of initiatib". UHC Comp8SS Sponsor of initiativv. Patient Academy Ir•mational F*dwati¢>n ofPharmaceuticaJ IFPMA Manuf•ttturnrJ & Asso¢i81ion# I Ingelheim QMSD Sponsor of initiatives: Globa5 Patients Co res& UHC Compass. Unmet atients Needs research Sponsor of initiatives: Global Patients Congress, AMATA Sponsor of initiativ Personalised Cancer Care Alliance 28
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Membership IAPO continued to strengthen its member network in 2025 supporting its 278 members. IAPO is currently implementing software to streamline the entire membership management, from outreach to invoicing and engagement. As of 31st December 2025, IAPO members were.. Region African members 43 Eastern Mediterranean members io European members 96 Latin American members 67 North Arnerican member5 24 South-East Asian member 14 Western Pacific member5 24 TOTAL 278 Membershlp Type 99 Associate 37 Network 142 Affiliate TOTAL 278 29
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Risk Management A risk register 15 prepared by the CEO and presented annually to the Board to discuss ensuring that there are effective and adequate risk management and internal control systems in place to manage the major risks to which the Charity is exposed. IAPO prepares the risk register by understanding the risk environment and its operations and then identifies the key risks. The CEO and the Treasurer then undert8kÈ a thorough analysis and evaluation of the risks identified before coming up with a treatment for the risks. Risks are identifi'ed under headings of Financial, Funding, Governance, Operational and Personnel, and mitig3tion actions detailed. IAPO aims to diversify its funding by approaching international trust funds, international development agencies and large programmes to raise non-industry partner funding. Scan the QR CO wwwJ•pfy.or8. 30
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Financial Review Financial position at the end of the period Incoming resources for the year amounted to £280,01712024.. £595,120), which was higher than the previous year due to a strategic increase in research and special projects funded by our partners. Expenditure in 2025 was £506,03412Q24.. £619.7591 Expenditure is also higher than the previous year, in line with the fact that we increased our output in research and Special Projects. Reserves Poliry The IAPO Board approved a reserves policy in September 2014, with a target level of free reserves of 6-12 months. running Costs. 6 month5 fLJnning cost is c.£132,280. This polity was set with due regard to guidance from the Charity Commission ICC19- Charity Reservesl and is reviewed annually. The level of unrestricted reserves, as at 31st December 2025 is £213,517. This is within the target in the reserves policy, and will be monitored by the Board of Trustees. Going Concern The trustees consider that there are no material uncertainties about the Charity's ability to conrinue as a going concern. Our current partners and funders have been very receptive to new proposals and wish to continue working with IAPO until the foSeeable future. IAPO funding transparency The Governing Board members declare relevant conflicts of interests and conflicts of loyalty at each Board meeting and between meetings. A register of interests is maintzined. Reference to IAPO'S code of conduct and policy regulating IAPO's relationship with, and independence from. sponsors can be found at www.iapo.org.uk/consensus-framework-ethical-collaboration and www.iapo.org.uk/healthcare-industry-partners. The overall proportion of industry to non-indu5try income for the year was approximately 99Y¢. 31
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 Pen5i0n arrangements IAPO operates an occupational pen5i0n scheme and a150 Operate5 a policy of contribukn"on5 directly into Staff members, chosen personal pension scheme5, Wlth no obligation for staff to make personal contributions. The issue of pension deficit, which would apply to an occupational scheme, does not therefore arise. IAPQ• 32
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees. Report ft>r the Year Ended 31 December 2025 Statement of Trustees, Responsibilities The trustees (who are also the directors of the company for the purposes of company lawl are responsible for preparing the trustees, annual report and financial statements in accordance with applitable law and United Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accounting Practicel. Company law requires the trustees to prepare fi'nancial statements for each financial period which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to.. select suitable accounting policies and then apply them consistently; observe the methods and principles in the Charities SORP,. make judgements and estimates that are reasonable and prudent,. State whether applicable UK Accounting Standards have been ft)Ilowed, subject to any material departLJres dlsclosed and explained in the financial statements- and 4 prepare the financial Statements on the going concern basis unless it 15 inappropriate to presume that the charitable charity will continue in business. The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time, the h"nancial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are a150 responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and disseminatr'on of financial statements may differ from legislation in other jurisdictions. Statement as to disclosure to our auditors In so far as the trustees are aware at the dzte of approving this report.. 4 there is no relevant audit information, being information needed by the auditor in connection with preparing their report, of which the charity's auditor is unaware,. and 33
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Trustees, Report ft>r the Year Ended 31 December 2025 4 the trustees having made enquiries of fellow directors and the group's auditor that they ought to have individually taken. have each taken all steps that helshe is obliged to take as a director in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information. Reappointment of auditors A proposal to reappoint Knox Cropper as the charity'5 Statutory auditor5 will be put to member5 at our forthcoming annual general meeting. Approved and authorised for issue by the Governing Board on 15 November 2025 and signed on their behalf by= Professor Lara Bloom Chair of IAPO Governing Board
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 Opinion We have audited the fi.nancial statements of International Alliance of Patients, Organization for the year ended 31 December 2025 which comprise the Statement of Financial Activities (including the Income and Expenditure Account). the Balance Sheet and the notes to the financial statements, including a summary of signilitant accounting polities. The linancial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accounting Practice), including Financial Reporknng Stsndard 102 'The Financial Reporknng Standard applicable in the UK and Republic of Ireland,. In our opinion the financial statements.. 4 Give a true and fair view of the state of the charitable company's affair5 as at 31 December 2025 and of it5 income and expenditure, for the period then ended; -> Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, and Have beèn preparèd in accordancè with the requirèments of the CompaniÈs Act 2006. Conclusions relating to going concern In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the linancial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast Slgnificant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the linancial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. Other information The other informatitsn comprise5 the information included in the Trustees, Report, other than the financial statements and our auditor'5 report thereon. The trustees are responsible for the other information. 35
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 Our opinion on the th'nancial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financi31 statement5, our responsibility is to re3d the other information and, in doing 50, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially rllisstated. If we identify such material inconsistencies Dr apparent material misstatements, we are required to determine whether there is a material misstatement in the fi'nancial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is 3 material mi55tatement of thi5 Other information, we are required to report that fact. We have nothing to report in this regard. Opinion on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit.. The information given in the Trustees, Report, which includes the directors, report prepared for the purp05e5 of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements,. and The directors, report, included within the Tru5tee5' Report, h35 been prepared in accordance with applicable legal requirernents. Matters on which we are Required to Report by Exception In the light of the knowledge and understanding of the charitsble company and its environment obtained in the course of the audit. we have not identified material misstatements in the Trustees, Report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires u5 to report to you if, in our opinion: -> Adequate a¢¢ountin8 records have not been kept, or return5 adequate for our audit have not been received from branche5 not visited by us,. or The financial statements a not in agreement with the accounting records and returns- or 4 Certain disclosures of Trustees, remuneration specified by law are not made,. or 4 We have not received all the information and explanation5 we require for our audit,. or 36
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 The trustees were not entitled to prepare the financial statements in accordance with the small corllpanies, regime and take advantage of the small cornpanies exemption from the requirement to prepare a Strategic Report or in preparing the Trustees, Report. Responslbllltles of Trustees As explained more fully in the Statement of Trustees, Responsibilities. the trustees (who are also the direttors of the charitable tompany for the purposes of tompany lawl are responsible for the preparation of the linancial statement5 and for being satisfied that they give a true and fair view, and for such internal control a5 the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement. whether due to fraud or error. In preparing the financial ststements, the trustees are responsible for assessing the Company's ability to continue as a going concern, disclosing, a5 applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. Auditor's responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement. whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in a¢¢ordance with ISAS IUKI will always detect a material misstatement when it exists. Mi55tatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irre8ularitie5, including fraud, Bre instances of non-cornpliance with laws and regulations. We design procedures in line with our responsibilitie5, Outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.. 4 The Charitable Company is required to comply with both company law and charity law and, based 4 The Charitable Company is required to comply with both company law and charity law and, based on our knowledge of its activities, we identified that the legal requirement to accurately account for restricted funds Wa5 of key significance. 37
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 We gained an understanding of how the ¢haritsble Company Complied with its legal and regulatory framework, including the requirement to properly account for restrirted funds, through discussions with management and a review of the documented policies, procedures and controls. 4 The audit team, which is Èxpèrièncèd in thè aLJdit of charitiès, considèred thè charitable company's susceptibility to material misstatement and how fraLJd may occur. Our consideration5 included the risk of management override. Our approach was to check that all restricted income was properly identilied and separately accounted for and to ensure that only valid and appropriate expenditure was charged to restricted funds. This included reviewing journal adjustments and unusual transaction5. A further description of our responsibilities for the audit of the )I'nancial statements is located on the Financial Reporting Council's website at.. htt www.frc.or .uk auditorsres onsibilities. This description forms part of our auditor's report. Use of our report This report is made solely to the charitable company's trustees. as a body. in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable cornp3ny'5 trustee5 those matter5 we are required to State to them in an auditors, report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Liv Burrell (Senior Statutory Auditor) For and on behalf of Knox Cropper LLP (Statutory Auditor) 65 Le8denh811 Street London EC3A 2AD 2810812026 38
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Statement of Financial Activities (incorporating an income and expenditure account) for the Year Ended 31 December 2025 Total 2025 Total 2024 t Unrestrlcted De$lgn•ted Re$trl¢ted (year) (year) Income from charitable activities: Nembership Healthcare Industry Partners APPC congress GPC congress Special Project5 Other charitable activitie5 193 81,336 51,867 51,867 64,762 64,762 145,208 18,180 145,208 488,499 25,092 18,180 Total 70.047 64,762 145.208 280.017 595.120 Expenditure on charitable Activities: Charitable artivitles.. Capacity building. advocacy and collaboration Asia Pacific Patients Congress 197,0941 197,0941 197,2061 Global Patients Congress 186,0081 186,0081 Special projects 1322,9321 1322,9321 1522,5531 Total (97.094) (86.008) {322.932) (506,034) (619,759) Net Income/(expendlture) (27,047) (21,246) {177,724) (226,017) (24,639) Transfers Net movement In funds 127,0471 121,2461 1177,7241 1226,0171 124,6391 Reconciliation of funds: Funds brought forward 240.564 (21.351) 301.390 520.603 545.242 Total funds carried forward 213,517 (42,597) 123,666 294,586 520,603 All transactions are derived from continuing activities. All recognised gains and losses are included in the Statement of Financial Activities. 39
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Balance Sheet as at 31 December 2025 Notes 2025 2024 Fixed assets Current assets Debtors Cash in hand and in bank 23,583 281,016 56,885 507,451 304,599 564,336 Creditors: amounts falling due within one year (10,013) 143,7331 Net current asset$ 294,586 520,603 Net assets 294,586 520,603 Funds Unrestricted Funds Designated Funds Restricted Funds 213,517 142,597) 123,666 240,564 121,3511 301,390 Total Funds 294,586 520,603 These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitsble companies. These flnanclal statements were approved and authorlsed for Issue by the Governlng Board on L l August 2026 and signed on their behalf by.. Professor Lara Bloom Ms. Flavia Kyomukama Chair Treasurer Reglstered company number.. 0849571 L (England and Wales) The notes on pages 41 to 51 form part of these financial statements. 40
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statements for the Year Ended 31 Detember 2025 4 Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and costs linked to th strategic management of the charity. All costs are allocated between expenditure categories of the SOFA on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, other costs are apportioned on the basis staff time incurred. The core elements of charitable expenditure are as follows.. Capacity Building: Realising active partnerships with patients, orEanisations, maximising their impact through capacity building. Advotaty.. Advocating internationally with a strong patients, voice on the relevant aspetts of healthcare policy. with the aim of influencing international. regional and national health agendas and policie5. Collaboration- Building cross-sertor alliance and working collabor2tively with like-minded medical and health professionals, policy makers, academics, researchers and industry representatives. 1.5 Funds General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes. Designated funds are funds which are'ring-fenced, to be used for the specific purpose of the congre55. Restricted funds are funds, which are to be used in accordance with specific restrictions imposed by the donor. The aim and use of the restricted fund 15 Set out in the notes of the financial statements. 1.6 Tangible fixed a55et5 and depreciation Capital expenditure on items costing £1,000 or higher are recorded as tangible fi'xed assets. Tangible fixed assets are stated at historical cost less depCiatiOn. Depreciation is provided to reflert the useful estimated economic life of computer equipment assets at a rate of 33°A per annum (reducing balance method). 41
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 l. Incoming re50urce5 Healthcare Industry Partners OTHER Projects Total GSK 37,204 14,663 37.204 14,663 145,208 82.942 Roche Projects Other income 145,208 82,942 82,942 51,867 145,208 280,017 Income Resources comparatiTve 2024 Healthcare Industry Partners OTHER Projects Total IFPMA 43,113 38,223 43,113 38,223 488,499 25,285 GSK Projerts other income 488,499 25,285 25,285 81,336 488,499 595,120 42
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 2. Congre55 Support 2025 APPC congress GPC congress Total PAPO Boehringer Ingelheim TFPMA Online Transattions 19,988 21,265 13,675 9,834 19,988 21,265 13,675 9,834 64,762 64,762 Congress Support 2024 APPC congress GPC congress Total There was no congress held in 2024 but IAPO is holding the GPC in November 2025 in the Philippine5. 43
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 3. Expenditure on Charitable Activities Staff Costs Other Costs Support Costs Total Capacity Building1 advocacy and collaboration 38,792 58,301 97,093 Congress 9,684 76,325 86,008 Speclal Projects 87,152 148,328 87,452 322,932 Total 135,628 224,653 145,753 506,034 Expenditure on Charitable Activities Comparative Staff Costs Other Costs Support Costs Totsl Capacity Buildingi advocacy and collaboration 22,870 74,113 96,983 Congress Special Projects 86,235 325,757 110,784 522,776 Total 109, 105 325,757 184,897 619,759 4. Analysis of support costs Capacity BuSldlngi advocacy and collaboration Congress SpecSal Projects Total Rent and Rates 420 630 1,050 other Office Costs Legal and Professlonal Fees 14,485 21,728 36,213 40,180 60,270 100,450 Audit Fees 3,216 4,824 8.040 Total 58,301 87,452 145,753 640/0 of the charity'5 total resources including activities, staff time, and professional expert15e -were dedicated to supporting our projects and ensuring the achievement of our deliverables. 44
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Analysis of support COSt5 comparative Capacity Building advocacy and collaboration Congress Special Projects Total Rent and Rates 3,000 4,500 7,500 Other offi Costs 30,149 44,839 74,988 LÈgal and Professional Féés 35,772 53,657 89,429 Audit Fees 5, 192 7,788 12,980 Total 74,113 110,784 184,897 45
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons 5. Tru5tee5 and staff remuneration The trustees received no muneration. The Charity also paid £8,506 on behalf of Trustees to allow them to ftjlfil their duties (2024.. £25,373). staff rèmuneratiTon and numbers Total 2025 Total 2024 Wages and salaries Social Security Pension costs 126,346 6,613 2,670 125,376 13,167 660 135,628 139.203 The average number of full and part-time employee5 during the year was 3. 1 individual employee received emoluments in excess of £60,00012024.. 1 in the band £60,001 to £70,000). Key management personnel costs amounted to £66,391 {2024.. £66.391). 46
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 6. Operating Surplus Operating surplus is stated after charging. Total 2025 Total 2024 Auditors Remuneration Depreciation of Assets Operating Lease Charges (office rental) 7,320 5,550 7,500 7. Fixed Assets Computer equipmént Cost Brought forward 4,169 Carried forward Depreciation Brought forward Charge for the year 4,169 CarrSed forward Net book value At 31 December 2024 At 31 December 2023 There are no charges or securltles held over any fixed assets. All fixed assets are held In the charity and none in the trading subsidiary. Depreciation was nil was in the previous period. 47
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 8. Debtors 2025 2024 Debtors Prepayments Accrued income 50,000 6,885 23,583 23,583 56,885 9. Creditors: amount falling due within one year 2025 2024 Creditors Deferred income Accruals 288 21,512 22,221 9,725 10.013 43,733 10. Analysis of net assets between funds Unrestricted Fund Designated Restricted Funds Funds Total Funds Current assets Current liabilities 223,530 110,0131 142,5971 123,666 304,599 (10,013) As at 31 December 2025 213,517 142,5971 123,666 294.586 48
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Analysis of net assets between funds compardtive Unrestricted Fund Designated Restricted Funds Fund5 Total Fund5 Current assets Current liabilities 262,946 (22,3821 301,390 564.336 (43,733) 121,3511 As at 31 December 2024 240,564 121,3511 301,390 520.603 The deficit in the designated fund is primarily due to the extra staff costs asSOClated with covering these events that we did not get funding for In the past. 11. Movement in funds 2025 At31 December 2024 Incoming Resources Resources Expended At31 December 2025 Transfers Unrestricted fund 240,564 70,047 (97,0941 213,517 esi nat APPC congress 33,978 33,978 GPC congress Africa congress Latln Congress (9,6171 122,241) 123,4711 64,762 (86,0081 (30,863) (22.241) (23,471) Special projects 301,390 145,208 1322,9321 123,666 520,603 280.017 {506.034) 294.586 49
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Movements in funds comparative Al31 December 2023 Lncorning Resources Resources Expended At31 December 2024 Transfers 231,149 106,621 (97,2061 240,564 Desi nated Fund5'. APPC congress GPC congress Africa congress Latin Congress 33,978 19,6171 122,2411 123,4711 33,978 (9,617) (22.241) (23,471) Special projert5 335,444 488,499 1522,5531 301,390 545,242 595, 120 1619,7591 520.603 so
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 12. SOFA- Comparative Totsl 2024 Unrestricted Designated Restricted (year) Income from charitable activities: Nembership Healthcare Industry Partners APPC congress GPC congress Special Projects Other charitable activities 193 81,336 193 81,336 488,499 488,499 25,092 25,092 Total 106.621 488,499 595,120 Expenditure on charitable Activities: Charitable activities'.- Capacity building. advocacy and collaboration 197,2061 197,2061 Asia Pacific Patients Congress Global Patients Congress Special projects {522,5531 1522,5531 Total (97,206) (522.553) {619,759) Net Income/(expendlture) 9,415 (34,054) (24,639) Trnnsfe Net movement in funds 9,415 134.0541 124,6391 Reconciliation of funds: Funds brought forward 231.149 (21,351) 335.444 545.242 Total funds carrled forward 240,564 (21,351) 301,390 520.603 Related Party Transactions There were no related party transactlons other than relmbursement of Trustee expenses as detalled In Note 6 12023.. nil) si
IAPO of Thank ou The Intemational of Patients, Or81zati5 is re&wtered in England and Wales as chwityn. n55577 and cOvanY knmted by 8uarwrtge n. 084957n Q Adckess Caropl 82 street Lorthry SEI 3GN L Websita WWtrvw¢xofgA*
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 Opinion We have audited the fi.nancial statements of International Alliance of Patients, Organization for the year ended 31 December 2025 which comprise the Statement of Financial Activities (including the Income and Expenditure Account). the Balance Sheet and the notes to the financial statements, including a summary of signilitant accounting polities. The linancial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accounting Practice), including Financial Reporknng Stsndard 102 'The Financial Reporknng Standard applicable in the UK and Republic of Ireland,. In our opinion the financial statements.. 4 Give a true and fair view of the state of the charitable company's affair5 as at 31 December 2025 and of it5 income and expenditure, for the period then ended; -> Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, and Have beèn preparèd in accordancè with the requirèments of the CompaniÈs Act 2006. Conclusions relating to going concern In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the linancial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast Slgnificant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the linancial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. Other information The other informatitsn comprise5 the information included in the Trustees, Report, other than the financial statements and our auditor'5 report thereon. The trustees are responsible for the other information. 35
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 Our opinion on the th'nancial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financi31 statement5, our responsibility is to re3d the other information and, in doing 50, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially rllisstated. If we identify such material inconsistencies Dr apparent material misstatements, we are required to determine whether there is a material misstatement in the fi'nancial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is 3 material mi55tatement of thi5 Other information, we are required to report that fact. We have nothing to report in this regard. Opinion on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit.. The information given in the Trustees, Report, which includes the directors, report prepared for the purp05e5 of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements,. and The directors, report, included within the Tru5tee5' Report, h35 been prepared in accordance with applicable legal requirernents. Matters on which we are Required to Report by Exception In the light of the knowledge and understanding of the charitsble company and its environment obtained in the course of the audit. we have not identified material misstatements in the Trustees, Report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires u5 to report to you if, in our opinion: -> Adequate a¢¢ountin8 records have not been kept, or return5 adequate for our audit have not been received from branche5 not visited by us,. or The financial statements a not in agreement with the accounting records and returns- or 4 Certain disclosures of Trustees, remuneration specified by law are not made,. or 4 We have not received all the information and explanation5 we require for our audit,. or 36
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 The trustees were not entitled to prepare the financial statements in accordance with the small corllpanies, regime and take advantage of the small cornpanies exemption from the requirement to prepare a Strategic Report or in preparing the Trustees, Report. Responslbllltles of Trustees As explained more fully in the Statement of Trustees, Responsibilities. the trustees (who are also the direttors of the charitable tompany for the purposes of tompany lawl are responsible for the preparation of the linancial statement5 and for being satisfied that they give a true and fair view, and for such internal control a5 the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement. whether due to fraud or error. In preparing the financial ststements, the trustees are responsible for assessing the Company's ability to continue as a going concern, disclosing, a5 applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. Auditor's responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement. whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in a¢¢ordance with ISAS IUKI will always detect a material misstatement when it exists. Mi55tatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irre8ularitie5, including fraud, Bre instances of non-cornpliance with laws and regulations. We design procedures in line with our responsibilitie5, Outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.. 4 The Charitable Company is required to comply with both company law and charity law and, based 4 The Charitable Company is required to comply with both company law and charity law and, based on our knowledge of its activities, we identified that the legal requirement to accurately account for restricted funds Wa5 of key significance. 37
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons IndependentAuditor'5 Report to the Members of International Alliance of Patients, Organization5 for the Year Ended 31st December 2025 We gained an understanding of how the ¢haritsble Company Complied with its legal and regulatory framework, including the requirement to properly account for restrirted funds, through discussions with management and a review of the documented policies, procedures and controls. 4 The audit team, which is Èxpèrièncèd in thè aLJdit of charitiès, considèred thè charitable company's susceptibility to material misstatement and how fraLJd may occur. Our consideration5 included the risk of management override. Our approach was to check that all restricted income was properly identilied and separately accounted for and to ensure that only valid and appropriate expenditure was charged to restricted funds. This included reviewing journal adjustments and unusual transaction5. A further description of our responsibilities for the audit of the )I'nancial statements is located on the Financial Reporting Council's website at.. htt www.frc.or .uk auditorsres onsibilities. This description forms part of our auditor's report. Use of our report This report is made solely to the charitable company's trustees. as a body. in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable cornp3ny'5 trustee5 those matter5 we are required to State to them in an auditors, report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Liv Burrell (Senior Statutory Auditor) For and on behalf of Knox Cropper LLP (Statutory Auditor) 65 Le8denh811 Street London EC3A 2AD 2810812026 38
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Statement of Financial Activities (incorporating an income and expenditure account) for the Year Ended 31 December 2025 Total 2025 Total 2024 t Unrestrlcted De$lgn•ted Re$trl¢ted (year) (year) Income from charitable activities: Nembership Healthcare Industry Partners APPC congress GPC congress Special Project5 Other charitable activitie5 193 81,336 51,867 51,867 64,762 64,762 145,208 18,180 145,208 488,499 25,092 18,180 Total 70.047 64,762 145.208 280.017 595.120 Expenditure on charitable Activities: Charitable artivitles.. Capacity building. advocacy and collaboration Asia Pacific Patients Congress 197,0941 197,0941 197,2061 Global Patients Congress 186,0081 186,0081 Special projects 1322,9321 1322,9321 1522,5531 Total (97.094) (86.008) {322.932) (506,034) (619,759) Net Income/(expendlture) (27,047) (21,246) {177,724) (226,017) (24,639) Transfers Net movement In funds 127,0471 121,2461 1177,7241 1226,0171 124,6391 Reconciliation of funds: Funds brought forward 240.564 (21.351) 301.390 520.603 545.242 Total funds carried forward 213,517 (42,597) 123,666 294,586 520,603 All transactions are derived from continuing activities. All recognised gains and losses are included in the Statement of Financial Activities. 39
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Balance Sheet as at 31 December 2025 Notes 2025 2024 Fixed assets Current assets Debtors Cash in hand and in bank 23,583 281,016 56,885 507,451 304,599 564,336 Creditors: amounts falling due within one year (10,013) 143,7331 Net current asset$ 294,586 520,603 Net assets 294,586 520,603 Funds Unrestricted Funds Designated Funds Restricted Funds 213,517 142,597) 123,666 240,564 121,3511 301,390 Total Funds 294,586 520,603 These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitsble companies. These flnanclal statements were approved and authorlsed for Issue by the Governlng Board on L l August 2026 and signed on their behalf by.. Professor Lara Bloom Ms. Flavia Kyomukama Chair Treasurer Reglstered company number.. 0849571 L (England and Wales) The notes on pages 41 to 51 form part of these financial statements. 40
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statements for the Year Ended 31 Detember 2025 4 Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and costs linked to th strategic management of the charity. All costs are allocated between expenditure categories of the SOFA on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, other costs are apportioned on the basis staff time incurred. The core elements of charitable expenditure are as follows.. Capacity Building: Realising active partnerships with patients, orEanisations, maximising their impact through capacity building. Advotaty.. Advocating internationally with a strong patients, voice on the relevant aspetts of healthcare policy. with the aim of influencing international. regional and national health agendas and policie5. Collaboration- Building cross-sertor alliance and working collabor2tively with like-minded medical and health professionals, policy makers, academics, researchers and industry representatives. 1.5 Funds General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes. Designated funds are funds which are'ring-fenced, to be used for the specific purpose of the congre55. Restricted funds are funds, which are to be used in accordance with specific restrictions imposed by the donor. The aim and use of the restricted fund 15 Set out in the notes of the financial statements. 1.6 Tangible fixed a55et5 and depreciation Capital expenditure on items costing £1,000 or higher are recorded as tangible fi'xed assets. Tangible fixed assets are stated at historical cost less depCiatiOn. Depreciation is provided to reflert the useful estimated economic life of computer equipment assets at a rate of 33°A per annum (reducing balance method). 41
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 l. Incoming re50urce5 Healthcare Industry Partners OTHER Projects Total GSK 37,204 14,663 37.204 14,663 145,208 82.942 Roche Projects Other income 145,208 82,942 82,942 51,867 145,208 280,017 Income Resources comparatiTve 2024 Healthcare Industry Partners OTHER Projects Total IFPMA 43,113 38,223 43,113 38,223 488,499 25,285 GSK Projerts other income 488,499 25,285 25,285 81,336 488,499 595,120 42
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 2. Congre55 Support 2025 APPC congress GPC congress Total PAPO Boehringer Ingelheim TFPMA Online Transattions 19,988 21,265 13,675 9,834 19,988 21,265 13,675 9,834 64,762 64,762 Congress Support 2024 APPC congress GPC congress Total There was no congress held in 2024 but IAPO is holding the GPC in November 2025 in the Philippine5. 43
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 3. Expenditure on Charitable Activities Staff Costs Other Costs Support Costs Total Capacity Building1 advocacy and collaboration 38,792 58,301 97,093 Congress 9,684 76,325 86,008 Speclal Projects 87,152 148,328 87,452 322,932 Total 135,628 224,653 145,753 506,034 Expenditure on Charitable Activities Comparative Staff Costs Other Costs Support Costs Totsl Capacity Buildingi advocacy and collaboration 22,870 74,113 96,983 Congress Special Projects 86,235 325,757 110,784 522,776 Total 109, 105 325,757 184,897 619,759 4. Analysis of support costs Capacity BuSldlngi advocacy and collaboration Congress SpecSal Projects Total Rent and Rates 420 630 1,050 other Office Costs Legal and Professlonal Fees 14,485 21,728 36,213 40,180 60,270 100,450 Audit Fees 3,216 4,824 8.040 Total 58,301 87,452 145,753 640/0 of the charity'5 total resources including activities, staff time, and professional expert15e -were dedicated to supporting our projects and ensuring the achievement of our deliverables. 44
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Analysis of support COSt5 comparative Capacity Building advocacy and collaboration Congress Special Projects Total Rent and Rates 3,000 4,500 7,500 Other offi Costs 30,149 44,839 74,988 LÈgal and Professional Féés 35,772 53,657 89,429 Audit Fees 5, 192 7,788 12,980 Total 74,113 110,784 184,897 45
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons 5. Tru5tee5 and staff remuneration The trustees received no muneration. The Charity also paid £8,506 on behalf of Trustees to allow them to ftjlfil their duties (2024.. £25,373). staff rèmuneratiTon and numbers Total 2025 Total 2024 Wages and salaries Social Security Pension costs 126,346 6,613 2,670 125,376 13,167 660 135,628 139.203 The average number of full and part-time employee5 during the year was 3. 1 individual employee received emoluments in excess of £60,00012024.. 1 in the band £60,001 to £70,000). Key management personnel costs amounted to £66,391 {2024.. £66.391). 46
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 6. Operating Surplus Operating surplus is stated after charging. Total 2025 Total 2024 Auditors Remuneration Depreciation of Assets Operating Lease Charges (office rental) 7,320 5,550 7,500 7. Fixed Assets Computer equipmént Cost Brought forward 4,169 Carried forward Depreciation Brought forward Charge for the year 4,169 CarrSed forward Net book value At 31 December 2024 At 31 December 2023 There are no charges or securltles held over any fixed assets. All fixed assets are held In the charity and none in the trading subsidiary. Depreciation was nil was in the previous period. 47
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 8. Debtors 2025 2024 Debtors Prepayments Accrued income 50,000 6,885 23,583 23,583 56,885 9. Creditors: amount falling due within one year 2025 2024 Creditors Deferred income Accruals 288 21,512 22,221 9,725 10.013 43,733 10. Analysis of net assets between funds Unrestricted Fund Designated Restricted Funds Funds Total Funds Current assets Current liabilities 223,530 110,0131 142,5971 123,666 304,599 (10,013) As at 31 December 2025 213,517 142,5971 123,666 294.586 48
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Analysis of net assets between funds compardtive Unrestricted Fund Designated Restricted Funds Fund5 Total Fund5 Current assets Current liabilities 262,946 (22,3821 301,390 564.336 (43,733) 121,3511 As at 31 December 2024 240,564 121,3511 301,390 520.603 The deficit in the designated fund is primarily due to the extra staff costs asSOClated with covering these events that we did not get funding for In the past. 11. Movement in funds 2025 At31 December 2024 Incoming Resources Resources Expended At31 December 2025 Transfers Unrestricted fund 240,564 70,047 (97,0941 213,517 esi nat APPC congress 33,978 33,978 GPC congress Africa congress Latln Congress (9,6171 122,241) 123,4711 64,762 (86,0081 (30,863) (22.241) (23,471) Special projects 301,390 145,208 1322,9321 123,666 520,603 280.017 {506.034) 294.586 49
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 Movements in funds comparative Al31 December 2023 Lncorning Resources Resources Expended At31 December 2024 Transfers 231,149 106,621 (97,2061 240,564 Desi nated Fund5'. APPC congress GPC congress Africa congress Latin Congress 33,978 19,6171 122,2411 123,4711 33,978 (9,617) (22.241) (23,471) Special projert5 335,444 488,499 1522,5531 301,390 545,242 595, 120 1619,7591 520.603 so
IAP Intemafjonal Alllance of Pafjent5' Organlzafjons Notes to the Financial Statement5 for the Year Ended 31 December 2025 12. SOFA- Comparative Totsl 2024 Unrestricted Designated Restricted (year) Income from charitable activities: Nembership Healthcare Industry Partners APPC congress GPC congress Special Projects Other charitable activities 193 81,336 193 81,336 488,499 488,499 25,092 25,092 Total 106.621 488,499 595,120 Expenditure on charitable Activities: Charitable activities'.- Capacity building. advocacy and collaboration 197,2061 197,2061 Asia Pacific Patients Congress Global Patients Congress Special projects {522,5531 1522,5531 Total (97,206) (522.553) {619,759) Net Income/(expendlture) 9,415 (34,054) (24,639) Trnnsfe Net movement in funds 9,415 134.0541 124,6391 Reconciliation of funds: Funds brought forward 231.149 (21,351) 335.444 545.242 Total funds carrled forward 240,564 (21,351) 301,390 520.603 Related Party Transactions There were no related party transactlons other than relmbursement of Trustee expenses as detalled In Note 6 12023.. nil) si
IAPO of Thank ou The Intemational of Patients, Or81zati5 is re&wtered in England and Wales as chwityn. n55577 and cOvanY knmted by 8uarwrtge n. 084957n Q Adckess Caropl 82 street Lorthry SEI 3GN L Websita WWtrvw¢xofgA*